Page 61 - ARNM-1-1

Advances in Radiotherapy &

Nuclear Medicine

CASE REPORT
PRaG regimens for rechallenge in a patient

with acquired resistance to PD-1 inhibitor in
advanced refractory renal pelvis carcinoma:

A case report

Zhihui Hong 1,2,3† , Hong Xu 4,5† , Yuehong Kong 5,6,7 , Meiling Xu 5,6,7 , Yifu Ma 5,6,7 ,
Pengfei Xing 5,6,7 *, and Liyuan Zhang 5,6,7 *

1 Department of Nuclear Medicine, The Second Affiliated Hospital of Soochow University, Suzhou,
215005 Jiangsu, China
2 State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou, 215123,
Jiangsu, China
3 INHC Key Laboratory of Nuclear Medicine and Jiangsu Key Laboratory of Molecular Nuclear
Medicine, Wuxi, 214063, Jiangsu, China
4 Department of Oncology, Changshu Hospital Affiliated to Soochow University, Suzhou, 215488
Jiangsu, China
5 Department of Radiotherapy and Oncology, The Second Affiliated Hospital of Soochow University,
Suzhou, 215005 Jiangsu, China
6 Institution of Radiotherapy and Oncology, Soochow University, Suzhou, 215123 Jiangsu, China
7 Laboratory for Combined Radiotherapy and Immunotherapy of Cancer, The Second Affiliated
† These authors contributed equally Hospital of Soochow University, Suzhou, 215005 Jiangsu, China
to this work.
*Corresponding authors:
Liyuan Zhang
(zhangliyuan@suda.edu.cn)
Pengfei Xing Abstract
(xingpf@hotmail.com)
Despite the burgeoning popularity of programmed death-1 (PD-1) inhibitors in cancer
Citation: Hong Z, Xu H, Kong Y,
2023, PRaG regimens for treatment, it is not uncommon for patients who initially respond to this therapy to
rechallenge in a patient with experience relapse over time. Here, we present the case of a patient with advanced
acquired resistance to PD-1 renal pelvis carcinoma who had received prior treatment with chemotherapy and
inhibitor in advanced refractory
renal pelvis carcinoma: A case PD-1 inhibitor therapy but ultimately experienced disease progression. Subsequently,
report. Adv Radiother Nucl Med, the patient underwent a combination therapy known as PRaG 2.0, which included
1(1): 0441. PD-1 inhibitor, radiotherapy, granulocyte-macrophage colony-stimulating factor,
https://doi.org/10.36922/arnm.0441
and interleukin-2, resulting in effective disease control without significant adverse
Received: April 13, 2023 events. The duration of disease control lasted for a period of 10 months.
Accepted: June 29, 2023
Published Online: July 12, 2023 Keywords: PD-1 inhibitor; Radiotherapy; PRaG therapy; Rechallenge; Renal pelvis
Copyright: © 2023 Author(s). carcinoma
This is an Open Access article
distributed under the terms of the
Creative Commons Attribution
License, permitting distribution,
and reproduction in any medium, 1. Background
provided the original work is
properly cited. PD-1 inhibitor has become a primary treatment modality in the management of various
advanced cancers, including renal pelvis carcinoma (RPC) . Since 2016, it has been
[1]
Publisher’s Note: AccScience
Publishing remains neutral with authorized by the United States Food and Drug Administration for the treatment of
regard to jurisdictional claims in patients with RPC . Nonetheless, the emergence of acquired resistance during PD-1
[2]
published maps and institutional
affiliations. inhibitor therapy can present a significant hurdle for clinicians. In this report, we
Volume 1 Issue 1 (2023) 1 https://doi.org/10.36922/arnm.0441